140 related articles for article (PubMed ID: 1785427)
1. [The activity of etoposide (VP16) in combination chemotherapy against human bladder cancer cells in vitro].
Hattori T; Satoh M; Terashima Y; Nishimura T; Akimoto M
Hinyokika Kiyo; 1991 Sep; 37(9):995-8. PubMed ID: 1785427
[TBL] [Abstract][Full Text] [Related]
2. [Chemotherapy of invasive bladder cancer].
Kotake T
Gan To Kagaku Ryoho; 1991 Nov; 18(14):2375-82. PubMed ID: 1952956
[TBL] [Abstract][Full Text] [Related]
3. [Combination chemotherapy of methotrexate, etoposide, adriamycin and cisplatin (M-EAP) for advanced urothelial cancer].
Hashimura T; Okumura K; Akao T; Nakagawa T
Hinyokika Kiyo; 1991 Jul; 37(7):685-8. PubMed ID: 1927767
[TBL] [Abstract][Full Text] [Related]
4. In-vitro cell growth of human urothelial tumor cell lines under exposure with IL-3, GM-CSF, G-CSF and by combined administration with methotrexate, vinblastine, adriamycin and cisplatin.
Block T; Treiber U; Geffken B; Vogel M; Hanauske AR; Busch R; Hartung R
Investig Urol (Berl); 1994; 5():91-4. PubMed ID: 7536524
[No Abstract] [Full Text] [Related]
5. M-VAC: methotrexate (MTX), vinblastine (VLB), adriamycin (ADM), and cisplatin (DDP) for metastatic and node positive carcinoma of the urothelium.
Sternberg CN; Yagoda A; Scher HI; Whitmore WF; Herr HW; Morse MJ; Sogani PC; Watson RC; Hollander PS; Fair WR
Prog Clin Biol Res; 1988; 260():481-5. PubMed ID: 3283768
[No Abstract] [Full Text] [Related]
6. Methotrexate, vinblastine, adriamycin and cisplatin (MVAC) chemotherapy for the treatment of advanced bladder carcinoma.
Balbay MD; Ozen H; Uluçay S; Sahin A; Ergen A; Koçal C; Remzi D
Int Urol Nephrol; 1993; 25(4):351-7. PubMed ID: 8276565
[TBL] [Abstract][Full Text] [Related]
7. Induction of drug-resistant bladder carcinoma cells in vitro: impact on polychemotherapy with cisplatin, methotrexate and vinblastine (CMV).
Rohde D; Brehmer B; Kapp T; Valdor M; Jakse G
Urol Res; 1998; 26(4):249-57. PubMed ID: 9759998
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
[TBL] [Abstract][Full Text] [Related]
9. [Usefulness of magnetic resonance imaging for evaluation of therapeutic efficacy of bone metastases from bladder cancer: a case report].
Urushibara M; Tsukamoto T; Horiuchi S; Negishi T
Hinyokika Kiyo; 1998 Jul; 44(7):501-3. PubMed ID: 9752607
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy of carcinoma of the prostate and testis: experimental study in vivo and in vitro].
Okada K; Kanamaru H; Yoshiki T; Hashimura T; Nishimura K; Hida S; Nishio Y; Oishi K; Yoshida O; Yamauchi T
Hinyokika Kiyo; 1988 Nov; 34(11):1911-6. PubMed ID: 2468265
[TBL] [Abstract][Full Text] [Related]
11. [MEP (methotrexate, etoposide and cisplatin) and M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced uroepithelial cancer--a preliminary report of MEP as second line chemotherapy for recurrence after M-VAC].
Seguchi T; Nakano E; Miki T; Kondoh M; Nishimura K; Nakamura N; Okuyama A
Gan To Kagaku Ryoho; 1994 Jan; 21(1):59-65. PubMed ID: 8291917
[TBL] [Abstract][Full Text] [Related]
12. [In vitro combined effects of pirarubicin (THP) and various antitumor drugs on human tumor cell lines].
Nagasawa M; Ishii S; Kariya Y; Itoh O; Yamamoto H; Kawaharajo K; Takeuchi T
Gan To Kagaku Ryoho; 1990 Apr; 17(4 Pt 1):633-8. PubMed ID: 2108612
[TBL] [Abstract][Full Text] [Related]
13. Possible alternative treatment for advanced transitional cell carcinoma of the urothelium (N+ and/or M+) in 1988.
Perrin P; Mouriquand P; Monsallier M; Devonec M
Prog Clin Biol Res; 1989; 303():617-9. PubMed ID: 2780666
[No Abstract] [Full Text] [Related]
14. Adjuvant chemotherapy for deep muscle-invasive transitional cell bladder carcinoma - a practice guideline.
Segal R; Winquist E; Lukka H; Chin JL; Brundage M; Markman BR;
Can J Urol; 2002 Oct; 9(5):1625-33. PubMed ID: 12431323
[TBL] [Abstract][Full Text] [Related]
15. Chemotherapy for advanced urothelial tract tumors: the M-VAC regimen.
Sternberg CN; Yagoda A; Scher HI
Prog Clin Biol Res; 1988; 277():45-51. PubMed ID: 3054909
[No Abstract] [Full Text] [Related]
16. Chemotherapy with [SP-4-3-(R)]-[1,1-cyclobutanedicarboxylato(2-)](2- methyl-1,4-butanediamine-N,N')platinum (CI-973, NK121) in combination with standard agents against murine tumors in vivo.
Elliott WL; Roberts BJ; Howard CT; Leopold WR
Cancer Res; 1994 Aug; 54(16):4412-8. PubMed ID: 8044790
[TBL] [Abstract][Full Text] [Related]
17. Clinical outcome in patients with locally advanced bladder carcinoma treated with conservative multimodality therapy.
George L; Bladou F; Bardou VJ; Gravis G; Tallet A; Alzieu C; Serment G; Salem N
Urology; 2004 Sep; 64(3):488-93. PubMed ID: 15351577
[TBL] [Abstract][Full Text] [Related]
18. Organ conservation in deeply invasive bladder cancer.
Fair WR
Prog Clin Biol Res; 1991; 370():119-26. PubMed ID: 1924440
[No Abstract] [Full Text] [Related]
19. [M-VAC chemotherapy for patients with lymph node metastases and/or locally advanced bladder carcinoma].
Igawa M; Ueki T; Ueda M; Okada K; Usui T; Ohnishi Y; Nakatsu H; Kume T; Kodama M; Masu C
Hinyokika Kiyo; 1989 Aug; 35(8):1323-7. PubMed ID: 2683648
[TBL] [Abstract][Full Text] [Related]
20. [Systemic chemotherapy in advanced bladder cancer. New aspects].
Jakse G
Wien Klin Wochenschr; 1987 Jan; 99(2):54-7. PubMed ID: 3564487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
